Alarelin Acetate 79561-22-1

98% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	Alarelin Acetate 79561-22-1
CAS No.	79561-22-1
Molecular Formula	C56H78N16O12
Molecular Weight	1167.34
Quality Standard	98% up by HPLC
Appearance	White powder
Sequence	Glp-His-Trp-Ser-Tyr-DAla-Leu-Arg-Pro-NHEt

COA of Alarelin Acetate

Items	Specifications	Results
Appearance	White or off-white powder	White powder
Solubility	Sparingly soluble in MeOH, soluble in water and 1% acetate acid	Sparingly soluble in MeOH, soluble in water and 1% acetate acid
HPLC	The principal peak in the chromatogram obtained with the test solution is similar in retention time to principal peak in the chromatogram obtained with the reference solution.	Conforms
Amino acid analysis
Arg	0.9-1.1	1.0
Ala	0.9-1.1	1.0
His	0.9-1.1	1.0
Leu	0.9-1.1	0.9
Pro	0.8-1.0	1.0
Tyr	0.9-1.1	1.0
Glu	0.9-1.1	1.0
Ser	0.7-1.0	0.7
	No more than the traces of the other amino acids are present.
MS	1167.3±1.0	1167.4
Related Substances	Unspecified impurity for each impurity: NMT1.0%	0.51%(single largest impurity)
Purity	NLT 98.0%	99.26%
Acetic acid	NMT12.0%	8.6%
Water	NMT7.0%	4.3%
Specific Optical Rotation	-46.0 °to -56.0°(anhydrous and acetic acid free subtance)	-48.0 °
Bacterial endotoxins	Less than 70IU/mg	Conforms
Assay	97.0%-103.0% (anhydrous and acetic acid free subtance)	99.4%
Residual solvent
Methanol	NMT 3000ppm	Conforms
Acetonitrile	NMT 410ppm	Conforms
Triethylamine	NMT 320ppm	Conforms
Conclusion	Meet the specification

Usage

Function of Alarelin Acetate

Alarelin is a nonapeptide analogue of synthetic gonadotropin-releasing hormone (GnRH), and its efficacy is 15 times that of the parent. In the early stage of medication, it can stimulate the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), causing a temporary increase in ovarian-derived steroid hormones; repeated medication can inhibit the release of LH and FSH from the pituitary, and reduce the level of estradiol in the blood. To achieve the effect of drug ovariectomy, at the same time it has a regulatory effect on the expression of the related oncogenes ras, neu, and myc of endometrial cancer. Clinically, it is mainly used to promote ovulation, treat infertility caused by abnormal ovarian function, endometriosis and uterine fibroids, and improve pregnancy rate.

Pharmacological action: This product is a nonapeptide analogue of synthetic gonadotropin releasing hormone (GnRH), which can stimulate the pituitary to release luteinizing hormone (LH) and follicle stimulating hormone (FSH) at the initial stage of treatment, causing transient ovarian-derived steroid hormones Increased; Repeated medication can inhibit the release of LH and FSH from the pituitary gland, reduce the level of estradiol in the blood, and achieve the effect of drug ovariectomy. This inhibitory effect can be used to treat hormone-dependent diseases such as endometriosis. The mechanism of action is to detect the expression of key intermediary proteins Smad2/3 and Smad7 in the TGF-β/smads signal transduction pathway in endometrial cancer transplanted tumor tissue, indicating that the TGF-β1/smads signal transduction pathway may be endometrial An important pathway in the pathogenesis of cancer. Alarelin may inhibit the occurrence and development of endometrial cancer by up-regulating Smad2/3 and down-regulating the expression of Smad7 protein. Pharmacokinetics: This product is rapidly absorbed after intramuscular injection in rats. The blood concentration reaches its peak in about 20 minutes, and the decrease in blood concentration is in line with the two-compartment model. When intramuscularly administered, t1/2α is about 0.2h, and t1/2β is about 1.8h. In intravenous administration, t1/2α is 0.08h, and t1/2β is about 1.2h. Its bioavailability can reach about 80%. The binding rate to plasma protein is 27% to 35%. The tissue distribution is by gonads and pituitary. The drug can be secreted from bile, completely metabolized and decomposed in the body within 24 hours, and all are excreted in urine and feces, of which 80% is in urine discharge.

Application: Clinically, it is mainly used to promote ovulation, treat infertility caused by abnormal ovarian function, endometriosis and uterine fibroids, and improve pregnancy rate.

Hot Tags : Alarelin Acetate Alarelin 79561-22-1 Alarelin powder Alarelin API Alarelin raw material

Send A Message

Related Products

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.